← Back to headlines
Eli Lilly's Obesity Pill Reportedly Trails Novo Nordisk's After Launch
Reports indicate that Eli Lilly's new obesity pill is trailing behind Novo Nordisk's competing product, even three months after its launch, suggesting a challenging market entry.
15 Jul, 13:28 — 15 Jul, 13:28
Sources
Showing 1 of 1 sources
